Delivery Order SPE2DE21D7020-SPE2D626F14A5
- Not listed
- Boston Scientific Corp, headquartered in Marlborough, Massachusetts, has been awarded a delivery order valued at $6,652.60 for enroute TCAR stents under a fixed-price contract with economic price adjustment provisions. The award, issued on October 30, 2025, with an ultimate completion date of November 6, 2025, represents a delivery order against an existing contract vehicle with the Defense Health Agency's Medical Supply Chain division. No small business set-aside was utilized for this award,...
- Boston Scientific Corp, headquartered in Marlborough, Massachusetts, has been awarded a delivery order valued at $3,326.30 for enroute TCAR (transcarotid) stents under the Defense Health Agency's Medical Supply Chain program. The award, issued December 11, 2025, with an ultimate completion date of December 18, 2025, carries fixed-price pricing with economic price adjustment provisions and was made without a small business set-aside. The delivery order will be performed at Boston Scientific's...
- Boston Scientific Corp, a leading global medical technology company headquartered in Marlborough, Massachusetts, was awarded a delivery order valued at $6,652.60 for enroute TCAR stents on September 26, 2025, with an ultimate completion date of October 3, 2025. This fixed-price contract with economic price adjustment was issued by the Defense Health Agency's Medical Supply Chain division and will be performed in Marlborough, MA. The contract represents no set-aside designation, allowing Boston...
- Boston Scientific Corp, headquartered in Marlborough, Massachusetts, was awarded a fixed-price delivery order valued at $7,593.10 by the Defense Health Agency's Medical Supply Chain on August 20, 2025, with an ultimate completion date of August 27, 2025. The contract involves the supply of enroute TCAR (transcarotid artery revascularization) stents, specialized cardiovascular intervention devices used in minimally invasive procedures. This delivery order was competitively awarded with no...
- Boston Scientific Corp has been awarded a delivery order valued at $11,389.65 for enroute TCAR stents under a Defense Health Agency Medical Supply Chain contract. The award, issued on September 2, 2025, with an ultimate completion date of September 9, 2025, represents a fixed-price contract with economic price adjustment provisions. The work will be performed at Boston Scientific's facility in Marlborough, Massachusetts. No set-aside designation was applied to this award, indicating open...
- Boston Scientific Corp, a leading global medical technology company headquartered in Marlborough, Massachusetts, was awarded a delivery order valued at $7,593.10 for EnRoute TCAR stents on August 14, 2025. This fixed-price contract with economic price adjustment is scheduled for ultimate completion by August 21, 2025, and will be performed at Boston Scientific's Marlborough facility. The award is being funded through the Defense Health Agency's Medical Supply Chain, a defense-focused federal...
- Boston Scientific Corp was awarded a delivery order valued at $3,326.30 by the Defense Health Agency's Medical Supply Chain for enroute TCAR stents, with performance in Marlborough, MA. The contract was awarded on August 12, 2025, with an ultimate completion date of August 19, 2025, and utilizes fixed-price pricing with economic price adjustment. This is an open competition award with no set-aside designation, allowing Boston Scientific to compete directly against other qualified vendors in...
- Boston Scientific Corp has been awarded a delivery order valued at $14,245.70 for EnRoute TCAR stents under a contract with the Defense Health Agency's Medical Supply Chain on August 26, 2025, with an ultimate completion date of September 3, 2025. This fixed-price contract with economic price adjustment provisions is unset-aside and will be performed at Boston Scientific's facility in Marlborough, Massachusetts. TCAR (Transcarotid Artery Revascularization) stents are specialized cardiovascular...
- Boston Scientific Corp, a leading global medical technology company headquartered in Marlborough, Massachusetts, was awarded a $5,447.25 delivery order by the Defense Health Agency's Medical Supply Chain for an Enroute Transcarotid Neuroprotection System with a completion date of October 21, 2025. This fixed-price contract with economic price adjustment features no set-aside designation, allowing Boston Scientific to compete openly in the federal marketplace. The award reflects the company's...
- The Defense Health Agency's Medical Supply Chain awarded a delivery order valued at $3,326.30 to Boston Scientific Corp for EnRoute TCAR stents on July 25, 2025, with an ultimate completion date of August 1, 2025. This fixed-price contract with economic price adjustment carries no set-aside designation, allowing Boston Scientific to compete openly in the federal marketplace. The work will be performed at Boston Scientific's facility in Marlborough, Massachusetts, where the company manufactures...
- SPE2DE21D7020Indefinite Delivery Contract
- SPE2DE21D7020-SPE2D626F14A5Delivery Order
Boston Scientific Corp has been awarded a delivery order valued at $10,948.60 for enroute TCAR (transcarotid neuroprotection) stents under a fixed-price contract with economic price adjustment provisions. The award was issued on December 12, 2025, by the Defense Health Agency's Medical Supply Chain division, with an ultimate completion date of December 19, 2025. The contract contains no small business set-aside designation and will be performed at Boston Scientific's facility in Marlborough, Massachusetts. This delivery order represents a tactical procurement supporting the federal government's cardiovascular intervention capabilities across defense and veterans healthcare networks. This award is issued against Boston Scientific's existing blanket purchase agreement with the Defense Health Agency, which provides the company with a structured vehicle for supplying specialized medical devices to military and veterans healthcare facilities. Boston Scientific, a global medical technology corporation headquartered in Marlborough, Massachusetts, serves as a critical supplier of advanced cardiovascular and interventional devices to federal healthcare agencies, including the Department of Veterans Affairs and Defense Health Agency. The company's portfolio of federal contract awards demonstrates its established capability to deliver complex medical devices and maintain supply chain continuity for essential treatment modalities across the defense and veterans healthcare enterprises.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.9k | 12/11/25 |